Literature DB >> 11315620

Histopathologic changes of thymoma preoperatively treated with corticosteroids.

H Tateyama1, E Takahashi, Y Saito, I Fukai, Y Fujii, H Niwa, T Eimoto.   

Abstract

Preoperative treatment of thymoma in advanced stages with corticosteroids may reduce the size of the tumor, but no precise histologic evaluation has been performed. We examined the histopathologic features of pretreatment biopsy and posttreatment surgical specimens of eleven cases of thymoma with such treatment to see the changes of the histologic subtypes based on Muller-Hermelink classification. All specimens were also assessed immunohistochemically for MIB-1 labeling and apoptotic cells to verify the effectiveness of this pretreatment. Seven tumors clinically diminished in size after the treatment with corticosteroids. Fungal infection occurred in three cases postoperatively. The histology of mixed thymomas (two cases) was converted to that of medullary thymoma. Predominantly cortical thymomas (four cases) and cortical thymomas (three cases) changed to show similar histologic features; both became epithelial-rich thymoma with large polygonal tumor cells having indistinct cell borders. In contrast, two well-differentiated thymic carcinomas showed at surgery more prominent squamoid appearance with distinct cell borders. The apoptotic indices of epithelial cells were increased (P = 0.001), and the MIB-1 indices tended to be decreased with corticosteroid treatment. These results suggest that there may be a histogenetic relationship between medullary and mixed thymomas and also between predominantly cortical and cortical thymomas. Corticosteroids may cause degenerative changes in the epithelial cells and lymphocytes and, in thymomas in advanced stages, corticosteroid pretreatment may be warranted, although attention should be paid to infection after surgery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315620     DOI: 10.1007/s004280000333

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  6 in total

1.  Rapid regression of stage IVb invasive thymoma under palliative corticosteroid administration.

Authors:  Taiki Fujiwara; Teruaki Mizobuchi; Kiyoshi Shibuya; Kenzo Hiroshima; Takehiko Fujisawa; Naomichi Iwai
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-04

2.  Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells.

Authors:  Yasunobu Funakoshi; Hiroyuki Shiono; Masayoshi Inoue; Yoshihisa Kadota; Mitsunori Ohta; Hikaru Matsuda; Meinoshin Okumura; Tadaaki Eimoto
Journal:  J Cancer Res Clin Oncol       Date:  2005-02-10       Impact factor: 4.553

3.  Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Giacomo Minicuci; Raffaella Riso; Laura Peri; Giovanni Scambia; Amelia Evoli
Journal:  J Clin Immunol       Date:  2007-11-14       Impact factor: 8.317

4.  Thymoma with dissemination: efficacy of macroscopic total resection of disseminated nodules.

Authors:  Motoki Yano; Hidefumi Sasaki; Haruhiro Yukiue; Osamu Kawano; Katsuhiro Okuda; Yu Hikosaka; Yoshitaka Fujii
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

5.  The effect of glucocorticoids on radiology and histology of thymoma in myasthenia gravis.

Authors:  Vasiliki Zouvelou; Ioannis Vamvakaris; Vasileios Tentolouris-Piperas; Konstantinos Potaris; Georgios Velonakis
Journal:  Acta Neurol Belg       Date:  2021-06-25       Impact factor: 2.471

6.  Nephrotic Syndrome and a Retroperitoneal Mass: A Case Report of a Patient with Recurrent Invasive Thymoma.

Authors:  Hiroaki Myoga; Tetsu Akimoto; Naoko Mato; Takakiyo Nakaya; Takuya Murakami; Hiromichi Yoshizawa; Saki Nakagawa; Atsushi Miki; Takahiro Masuda; Takahisa Kobayashi; Yuko Ono; Osamu Saito; Yoshihiko Ueda; Shigeaki Muto; Daisuke Nagata
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.